Growth Metrics

Novavax (NVAX) Cash & Current Investments (2016 - 2025)

Novavax (NVAX) has 16 years of Cash & Current Investments data on record, last reported at $735.1 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 20.37% year-over-year to $735.1 million; the TTM value through Dec 2025 reached $735.1 million, down 20.37%, while the annual FY2025 figure was $735.1 million, 20.37% down from the prior year.
  • Cash & Current Investments reached $735.1 million in Q4 2025 per NVAX's latest filing, down from $762.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.0 billion in Q1 2021 and bottomed at $8.2 million in Q3 2021.
  • Average Cash & Current Investments over 5 years is $743.6 million, with a median of $678.2 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: soared 15564.6% in 2022, then crashed 99.19% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $11.5 million in 2021, then surged by 11535.19% to $1.3 billion in 2022, then plummeted by 57.48% to $568.5 million in 2023, then soared by 62.38% to $923.1 million in 2024, then dropped by 20.37% to $735.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $735.1 million in Q4 2025, $762.9 million in Q3 2025, and $612.3 million in Q2 2025.